A Pooled Analysis of Telithromycin in the Treatment of Community-Acquired Respiratory Tract Infections in Adults

Infection

Volumn 31, Issue 5, 2003, Pages 308-317

  Carbon, C ^a  

^a NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ERYTHROMYCIN; PENICILLIN G; TELITHROMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; CARDIOTOXICITY; CHRONIC BRONCHITIS; CLINICAL STUDY; CLINICAL TRIAL; COMMUNITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; HEART ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATHOGENESIS; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; QT INTERVAL; RESPIRATORY TRACT INFECTION; SINUSITIS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TONSILLITIS; TREATMENT INDICATION; TREATMENT OUTCOME; VERTIGO; VISUAL IMPAIRMENT; VOMITING;

EID: 0141956457     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-003-3142-1     Document Type: Article

References (60)

1. Bartlett JG: IDCP guidelines: management of upper respiratory tract infections. Infect Dis Clin Pract 1997; 6: 212-220.
2. Garau J: The clinical impact of macrolide resistance in pneumococcal respiratory infections. Int J Antimicrob Agents 2001;18 (Suppl. 1): 33-38.
3. Ball P: Therapy for pneumococcal infection at the millennium: doubts and certainties. Am J Med 1999; 107(Suppl. 1A): 77-85.
4. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ: Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31: 347-382.
5. Thornsberry C, Ogilvie P, Kahn J, Mauriz Y: Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the United States in the 1996-1997 respiratory season. Diagn Microbiol Infect Dis 1997; 29: 249-257.
6. Felmingham D, Grüneberg RN, and the Alexander Project Group: The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother 2000; 45: 191-203.
7. World Health Organization (WHO): Containing antimicrobial resistance: review of the literature and report of the WHO workshop on the development of a global strategy for the containment of antimicrobial resistance. Report No. WHO/CDS/CSR/DRS/99.2. WHO, Geneva 1999.
8. World Health Organization (WHO): WHO Global strategy for containment of antimicrobial resistance. Report No. WHO/CDS/CSR/DRS/2001.2. WHO, Geneva 2001.
9. Felmingham D: Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. J Infect 2002; 44(Suppl. A): 3-10.
10. Hsush PR, Chen HM, Huang AY, Wu JJ: Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan. Antimicrob Agents Chemother 1995; 39: 2239-2242.
11. Jasir A, Schalen C: Survey of macrolide resistance phenotypes in Swedish clinical isolates of Streptococcus pyogenes. J Antimicrob Chemother 1998; 41: 135-137.
12. Giovanetti E, Montanari MP, Mingola M, Varaldo PE: Phenotypes and genotypes of erythromycin-resistant Streptococcus pyogenes strains in Italy and heterogeneity in inducibly resistant strains. Antimicrob Agents Chemother 1999; 43: 1935-1940.
13. Tait-Kamradt A, Davies T, Appelbaum PC, Depardieu F, Courvalin P, Petitpas J, Wondrack L, Walker A, Jacobs MR, Sutcliffe J: New mechanisms of macrolide resistance from Eastern Europe and North America. Antimicrob Agents Chemother 2000; 44: 3395-3401.
14. Austin DJ, Kristinsson KG, Anderson RM: The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc Natl Acad Sci USA 1999; 96: 1152-1156.
15. Baquero JF: Evolving resistance patterns of Streptococcus pneumoniae: a link with long-acting macrolide consumption? J Chemother 1999; 11: 35-43.
16. Chen DK, McGeer A, de Azavedo JC, Low DE: Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
17. Granizo JJ, Aguilar L, Casal J, Garcia-Rey C, Dal Re R, Baquero F: Streptococcus pneumoniae resistance to macrolide and β-lactam consumption in Spain (1979-1997). J Antimicrob Chemother 2000; 46: 767-773.
18. Hyde TB, Gay K, Stephens DS, Vugia DJ, Pass M, Johnson S, Barrett NL, Schaffner W, Cieslak PR, Maupin PS, Zell ER, Jorgensen JH, Facklam RR, Whitney CG: Active Bacterial Core Surveillance/ Emerging Infections Program Network: macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857-1862.
19. Gonzales R, Steiner JF, Sande MA: Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA 1997; 278: 901-904.
20. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vazuelle-Kervroedan F, Bouvenot G, Eschwege E: Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365-370.
21. Spiritus E: Antibiotic usage for respiratory tract infections in an era of rising resistance and increased cost pressure. Am J Manag Care 2000; 6 (Suppl. 23): 1216-1221.
22. Sclar DA, Tartagione TA, Fine MJ: Overview of issues related to medical compliance with implications for the outpatient management of infectious diseases. Infect Agents Dis 1994; 3: 266-273.
23. Claxton AJ, Cramer J, Pierce C: A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
24. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfield LA, Kapoor WN: Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141.
25. Kelley MA, Weber DJ, Gilligan P, Cohen MS: Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-1011.
26. Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF: Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30: 520-528.
27. www.europa.eu.int
28. www.who.int/emc/amr.html
29. European Society Task Force Report: Guidelines for the management of community-acquired lower respiratory tract infections. Eur Resp J 1998; 11: 986-991.
30. Bernstein JM: Treatment of community-acquired pneumonia -IDSA guidelines. Chest 1999;115 (Suppl. 3): 9-13.
31. Brook I: Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. Ann Otol Rhinol Laryngol 2000; 109: 2-20.
32. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG: Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-1408.
33. Sinus and Allergy Health Partnership: Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000; 123: 5-31.
34. British Thoracic Society: British Thoracic Society Guidelines for the management of community-acquired pneumonia in adults. Thorax 2001;56 (Suppl. 4): 1-64.
35. Fendrick AM, Saint S, Brook I, Jacobs MR, Pelton S, Sethi S: Diagnosis and treatment of upper respiratory tract infections in the primary care setting. Clin Ther 2001; 23: 1683-1706.
36. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia. Am J Crit Care Med 2001; 163: 1730-1754.
37. Felmingham D, Hoban D, Zhanel G: Activity of the ketolide antimicrobial telithromycin against typical community-acquired respiratory pathogens. J Antimicrob Chemother 2001;48 (Suppl. B): 33-42.
38. Roblin PM, Hammerschlag MR: In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 1515-1516.
39. Schülin T, Wennersten CB, Ferraro MJ, Moellering RC, Eliopoulous GM: Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother 1998; 42: 1520-1523.
40. Edelstein PH, Edelstein MAC: In vitro activity of the ketolide HMR 3647 (RU 6647) for Legionella spp., its pharmacokinetics in guinea pigs, and use of the drug to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1999; 43: 90-95.
41. Bébéar CM, Renaudin H, Bryskier A, Bébéar C: Comparative activities of telithromycin (HMR 3647), levofloxacin and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother 2000; 44: 1980-1982.
42. Rastogi N, Seng Goh K, Berchel M, Bryskier A: In vitro activities of the ketolides telithromycin (HMR 3747) and HMR 3004 compared to those of clarithromycin against slowly growing mycobacteria at pHs 6.8 and 7.4. Antimicrob Agents Chemother 2000; 44: 2848-2852.
43. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC: In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother 2000; 44: 414-417.
44. B resistance induction by the ketolide telithromycin (HMR 3647): role of the 3-keto group (abstr. 02.10). In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones. ICMAS, Inc. and the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones, Georgia 2000, p 24.
45. Khair OA, Andrews JM, Honeybourne D, Jevons G, Vacheron F, Wise R: Lung concentrations in telithromycin after oral dosing. J Antimicrob Chemother 2001; 47: 837-840.
46. Muller-Serieys C, Soler P, Cantalloube C, Lemaitre F, Pham Gia H, Brunner F, Andremont A: Broncho-pulmonary disposition of the ketolide antimicrobial, telithromycin (HMR 3647). Antimicrob Agents Chemother 2001; 45: 3104-3108.
47. Leroy B: Telithromycin (HMR 3647), the first ketolide antimicrobial, exhibits excellent penetration into respiratory tract tissues and fluids: a review (abstr. G-8). In: Program and Abstracts of the 1st International Symposium on Gram-positive Infections. Organizing Committee of the 1st International Symposium on Gram-positive Infections, Texas 2000, p G-8.
48. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E: Efficacy and tolerability of once-daily therapy with telithromycin compared with high-dose amoxicillin for the treatment of community-acquired pneumonia. Infection 2002; 30: 378-386.
49. Tellier G, Hassman J, Leroy B, Sidarous E, Youngblood D: Oral telithromycin (HMR 3647) 800 mg once daily is well tolerated and as effective as oral clarithromycin 500 mg twice daily in community acquired pneumonia (CAP) in adults. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20,2000, Toronto, Canada. American Society for Microbiology, Washington DC, 2000, p 471.
50. Pullman J, Champlin J, Vrooman PS: Efficacy and tolerability of once daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. Int J Clin Pract 2003; 57: 377-384.
51. Carbon C, Moola S, Velancsics I, Leroy B, Rangaraju M, Decosta P: Efficacy of telithromycin, a new once-daily ketolide antimicrobial, in the treatment of community-acquired pneumonia. Clin Microbiol Infect 2003; 9: 691-703.
52. van Rensburg DJ, Matthews PA, Leroy B: Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Med Res Opin 2002; 18: 397-400.
53. Fogarty C, Patel TC, Galbraith H, Zuberbuhler GA, Leroy B: Efficacy of the first ketolide antibacterial, telithromycin, in the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae [abstr. L-857]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2001, Chicago, IL, USA. American Society for Microbiology, Washington DC 2001, p 449.
54. Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, Bienfait-Beuzon C: Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002; 96: 862-887.
55. Zervos MJ, Heyder AM, Leroy B: Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. J Int Med Res 2003; 31: 157-169.
56. Roos K, Brunswig-Pitschner C, Kostrica R, Pietola M, Leroy B, Rangaraju M, Boutalbi Y: Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002; 48: 100-108.
57. Luterman A, Tellier G, Lasko B, Leroy B: Efficacy and tolerabilitiy of the ketolide telithromycin (HMR 3647) for 5 or 10 days vs amoxicillin/ clarulanic acid for 10 days in treatment of acute maxillary sinusitis (AMS) in adults. Ear, Nose Throat 2003 (in press).
58. Buchanan P, Stephens T, Leroy B: Telithromycin vs cefuroxime axetil in acute maxillary sinusitis. Am J Rhinol 2003 (in press).
59. Norrby SR, Rabie W, Bacart P, Mueller O, Leroy B, Rangaraju M, Butticaz-Iroudayassamy E: Efficacy of short-course therapy with the ketolide telithromycin compared with 10 days' penicillin V in the treatment of pharyngitis/tonsillitis. Scand J Infect Dis 2001; 33: 883-890.
60. Quinn J, Ruoff GE, Ziter PS: Efficacy and tolerability of 5-day, once-daily telithromycin compared with 10-day, twice-daily clarithromycin for the treatment of goup A beta-hemolytic streptococcal tonsillitis/pharyngitis: a multicenter, randomized, double-blind, parallel-group study. Clin Ther 2003; 25: 422-443.